StockNews.AI
AMRX
StockNews.AI
202 days

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

1. Amneal will release its Q4 and full year 2024 results on Feb 28, 2025. 2. An audio webcast will provide insights into the financial performance. 3. Amneal is expanding its portfolio in complex and specialty pharmaceuticals.

Earnings
-0.57%Current Return
VS
+0.25%S&P 500
$8.7301/29 08:48 AM EDTEvent Start
$8.6801/30 03:03 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings may not significantly alter investor sentiment without prior expectations set.

How important is it?

Earnings release is crucial, but lack of major developments limits impact.

Why Short Term?

Earnings announcements typically have immediate but temporary effects on stock prices.

Related Companies

AMRX
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this here. The access code for the call is 863159. A replay of the conference call will be posted shortly after the call. About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn.

Related News